Lenvatinib
Liver And Intrahepatic Bile Duct Neoplasm
Explore 21 assets in Liver And Intrahepatic Bile Duct Neoplasm →Floatz Rating
B58/100
Confidence
Indicative
Sponsor
Sun Yat-sen University
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
45Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04618367CT.gov HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT | — | Completed | — | — | — |
NCT05555316CT.gov TACE Combined With Lenvatinib and MWA in the Treatment of Locally Advanced Large Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT04008797CT.gov A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Liver And Intrahepatic Bile Duct Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Lenvatinib (this asset) | Sun Yat-sen University | P2 | B · 58 |
| Irinotecan | Tehran University of Medical Sciences | P4 | BBB |
| Chlorhexidine | Changhua Christian Hospital | P4 | BB |
| Albumin Aggregated | Sirtex Medical | P4 | BB |
| Talaporfin | Light Sciences Oncology | P3 | BB |
| Oxaliplatin | Shanghai Zhongshan Hospital | P4 | BB |
| Indocyanine Green | Hospital Universitari Vall d'Hebron Research Institute | P4 | BB |
| Hep-V Vax | University of Oxford | P4 | BB |
| Fluorouracilum | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | P4 | BB |
+41 more in the Liver And Intrahepatic Bile Duct Neoplasm cohort
Other indications for Lenvatinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Portal Vein Thrombosis | — | P4 | BBB · 73 |
| Ovarian Carcinoma | — | P4 | BB · 70 |
| Hepatocellular Carcinoma | — | P4 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Lenvatinib in Liver And Intrahepatic Bile Duct Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/lenvatinib-liver-and-intrahepatic-bile-duct-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →